D-1060-2020 Class II Terminated

Recalled by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc — Greenville, SC

FDA drug recall D-1060-2020 was initiated by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc on Mar 19, 2020 and is designated Class II. Reason for recall: SubPotent Drug: Low out-of-specification results for assay testing. The recall status is terminated (terminated Sep 22, 2021). Affected quantity: 7416 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 1, 2020
Initiation Date
Mar 19, 2020
Termination Date
Sep 22, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7416 bottles

Product description

Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associates, Inc., Greenville, SC 29605; NDC 0121-0810-16.

Reason for recall

SubPotent Drug: Low out-of-specification results for assay testing.

Distribution pattern

Nationwide in the USA.

Code information

Lot: BE85, Exp. 11/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1060-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1060-2020. Report a data issue: hello@regdatalab.com.